Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy.
作者信息
Taiwo Babafemi O, Quiñones-Mateu Miguel E, Smith Kimberly, Zheng Lu, Gulick Roy, Nyaku Amesika N, Sax Paul E, Ha Belinda, Kumwenda Johnstone, Olefsky Maxine, Godfrey Catherine, Wallis Carole
机构信息
Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.
出版信息
AIDS Res Hum Retroviruses. 2020 Apr;36(4):254-255. doi: 10.1089/AID.2019.0253. Epub 2020 Mar 9.
Abstract
摘要
相似文献
1
Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy.多替拉韦加拉米夫定联合治疗耐药的既往病例。
AIDS Res Hum Retroviruses. 2020 Apr;36(4):254-255. doi: 10.1089/AID.2019.0253. Epub 2020 Mar 9.
2
Lamivudine-resistant HIV is durably suppressed with dolutegravir plus lamivudine dual therapy in humanised mice.在人源化小鼠中，对拉米夫定耐药的艾滋病毒通过多替拉韦加拉米夫定联合疗法得到持久抑制。
J Glob Antimicrob Resist. 2020 Mar;20:316-317. doi: 10.1016/j.jgar.2020.01.018. Epub 2020 Feb 13.
3
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.简报：多替拉韦加拉米夫定与多替拉韦富马酸替诺福韦二吡呋酯/恩曲他滨相比，基线病毒载量的病毒学应答：汇总分析。
J Acquir Immune Defic Syndr. 2020 May 1;84(1):60-65. doi: 10.1097/QAI.0000000000002302.
4
Bictegravir and dolutegravir: head to head at 96 weeks.比克替拉韦与多替拉韦：96周疗效对比
Lancet HIV. 2019 Jun;6(6):e342-e343. doi: 10.1016/S2352-3018(19)30135-3. Epub 2019 May 5.
5
6
Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir" by Calza .关于卡尔扎的《转换为拉米夫定联合多替拉韦或拉替拉韦治疗的HIV感染受抑制患者的体重和体脂质量无显著变化》
AIDS Res Hum Retroviruses. 2021 May;37(5):333-334. doi: 10.1089/AID.2020.0274. Epub 2021 Mar 15.
7
Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice.多替拉韦联合拉米夫定作为一线治疗方案用于多中心队列中HIV-1感染患者：来自临床实践的初步数据。
AIDS Res Hum Retroviruses. 2020 Jan;36(1):4-5. doi: 10.1089/AID.2019.0147. Epub 2019 Sep 30.
8
Dolutegravir plus lamivudine for hiv treatment: Does the historical genotype really matter?多替拉韦加拉米夫定用于HIV治疗：既往基因型真的重要吗？
EBioMedicine. 2020 Jun;56:102820. doi: 10.1016/j.ebiom.2020.102820. Epub 2020 Jun 5.
9
No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine--dolutegravir.转换为拉米夫定-多替拉韦的病毒学抑制的HIV阳性患者的体脂量无显著变化。
AIDS. 2020 May 1;34(6):956-957. doi: 10.1097/QAD.0000000000002495.
10
Inadvertent dual therapy with dolutegravir and lamivudine in a pregnant patient living with HIV. A case report.一名感染艾滋病毒的孕妇意外接受多替拉韦和拉米夫定联合治疗。病例报告。
Enferm Infecc Microbiol Clin (Engl Ed). 2021 Jun-Jul;39(6):305-306. doi: 10.1016/j.eimce.2021.04.003. Epub 2021 May 3.
本文引用的文献
1
Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.多替拉韦+拉米夫定用于HIV-1感染的两药抗逆转录病毒疗法的耐药屏障观点。
AIDS Res Hum Retroviruses. 2020 Jan;36(1):13-18. doi: 10.1089/AID.2019.0171. Epub 2019 Oct 21.
2
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.多替拉韦加拉米夫定与多替拉韦富马酸酯替诺福韦二吡呋酯和恩曲他滨在初治 HIV-1 感染的成人中的疗效比较（GEMINI-1 和 GEMINI-2）：两项多中心、双盲、随机、非劣效性、3 期临床试验的第 48 周结果。
Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9.
3
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.ACTG A5353：多替拉韦加拉米夫定用于治疗 HIV-1 载量<500000 拷贝/mL 的初治 HIV-1 感染者的一项先导研究。
Clin Infect Dis. 2018 May 17;66(11):1689-1697. doi: 10.1093/cid/cix1083.
4
Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism.基于深度测序的灵敏HIV-1基因分型检测方法，可同时测定对蛋白酶、逆转录酶、整合酶和成熟抑制剂的敏感性，以及HIV-1共受体嗜性。
Antimicrob Agents Chemother. 2014;58(4):2167-85. doi: 10.1128/AAC.02710-13. Epub 2014 Jan 27.
Zotero 插件